Febrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: A retrospective cohort study on duration of prophylactic GCSF administration

Lee, C F; Zhou, K.R.; Young, W M; Wong, C; Ng, TY; Lee, S F; Leung, Kwok‐Yin; Wong, Lucas; So, KW; Tang, William; Chong, Geoffrey; Chan, Sherry K.W.; Yip, Y T E; M, V Y; Yeung, Anita P C; Chin, Cindy; Kwan, Myung; Tsang, Hhc

doi:10.1007/s00520-019-05111-6

Cited by 4 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 However, infective complications of therapy have always been a significant toxicity concern. [6][7][8][9][10] These concerns have led to efforts to define The Goldilocks Zone for these patients with the use of pathology and genomic platforms to identify patients who do not need chemotherapy along with hematologic growth factor support and digital therapeutics to help those who do. 11 Despite these developments, adjuvant chemotherapy remains a significant cause of patient morbidity and mortality.…”

Section: Introductionmentioning

confidence: 99%

Breeching “The Goldilocks Zone”: Tetraplegia as a Rare Life-Altering Infective Complication of Adjuvant Breast Cancer Chemotherapy

et al. 2022

View full text Add to dashboard Cite

Background: Adjuvant chemotherapy has been an integral component of breast cancer care for decades. Advances in supportive care have been made, but despite this, infective complications of therapy remain a significant toxicity concern. Case Presentation: A premenopausal patient presented to the emergency department during the third wave of the Covid-19 pandemic with sepsis after a second course of adjuvant docetaxel-cyclophosphamide chemotherapy. Overnight she developed tetraplegia. An urgent MRI cervical spine revealed a pre-vertebral, vertebral, and epidural abscess. This was treated with an emergency C4-C7 posterior cervical laminectomy and decompression. Her inpatient care involved a protracted ICU admission followed by rehabilitation. She remains tetraplegic and requires continued inpatient care over a year after presentation. Restricted pandemic-related hospital visiting has compounded the impact of her illness. Conclusion: Infective complications of adjuvant breast cancer chemotherapy remain an issue despite advances in supportive care. This case highlights the devastating, life-altering impact that these complications can have as emphasized by the inclusion of the patient’s perspective.

show abstract

Section: Introductionmentioning

confidence: 99%

Breeching “The Goldilocks Zone”: Tetraplegia as a Rare Life-Altering Infective Complication of Adjuvant Breast Cancer Chemotherapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…12 According to the research of Lee et al, DTX intervention for BC patients can prevent and reduce the incidence of febrile neutropenia and the hospitalization rate of patients. 13 Another study reported that TZ combined with DTX (TZ+DTX) is the main drug to treatment HER-2+ BC, 14 indicating that TZ+DTX is feasible for the treatment of HER-2+ BC.…”

Section: Introductionmentioning

confidence: 99%

Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy

Feng¹,

Xian-zhi²,

Sun³

et al. 2021

CMAR

View full text Add to dashboard Cite

Objective: To explore the influence of trastuzumab (TZ) combined with docetaxel (DTX) on serum tumor markers (TMs) in the treatment of human epidermal growth factor receptor 2-positive (HER-2+) breast cancer (BC) and to analyze the factors influencing therapeutic efficacy. Methods: Ninety-six patients with HER-2+ BC treated in the First Affiliated Hospital of Anhui University Of Science and Technology from January 2019 to December 2020 were selected. According to different treatment plans, the patients were divided into two arms with 48 cases each. The control group (CG) was treated with DTX, and the research group (RG) was given TZ combined with DTX (TZ+DTX). The two arms were compared regarding the following aspects: curative effects, adverse reaction, alterations of TMs and inflammatory factors (IFs), and quality of life. Logistic regression analysis was performed to analyze the factors affecting the efficacy of patients. Results: After treatment, the TMs carcinoembryonic antigen (CEA), carbohydrate antigen (CA)125 and CA15-3 were significantly lower in RG compared with CG. The levels of IFs C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) were also lower in CG. The overall response rate and the Karnofsky performance status (KPS) score were significantly higher in RG. No evident difference was observed in the total incidence of adverse reactions between the two arms. The high expression of CEA, CA125 and CA15-3 as well as DTX monotherapy increased the risk of adverse prognosis. Conclusion: TZ+DTX can effectively improve the clinical efficacy of HER-2+ BC patients and reduce their levels of serum TMs and IFs.

show abstract

Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer

Belle

Hurvitz

Gilbar

et al. 2021

Breast Cancer Res Treat

View full text Add to dashboard Cite

Febrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: A retrospective cohort study on duration of prophylactic GCSF administration

Cited by 4 publications

References 18 publications

Breeching “The Goldilocks Zone”: Tetraplegia as a Rare Life-Altering Infective Complication of Adjuvant Breast Cancer Chemotherapy

Breeching “The Goldilocks Zone”: Tetraplegia as a Rare Life-Altering Infective Complication of Adjuvant Breast Cancer Chemotherapy

Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy

Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer

Contact Info

Product

Resources

About